Within the the biopharmaceutical industry, the global monoclonal antibody (mAb) market exceeded $80 billion in 2013 and is predicted to top $100 billion in 2015.
To sustain this rapid market growth going forwards, the industry requires increasingly efficient mAb purification processes to progress from discovery to commercial manufacturing.
A novel purification approach that significantly increases the performance of the mAb purification process by enhancing the efficiency of the Protein A column has recently been investigated by Catalent Pharma Solutions, based in Somerset, New Jersey and 3M Purification.
3M’s Emphaze AEX Hybrid Purifier – a single-use chromatography purification product – has been designed to help biopharmaceutical manufacturers achieve high product purity early in the manufacturing process in order to markedly improve efficiency and process economics.
Three core 3M core technologies – advanced polymeric materials, fine fibre nonwovens and porous membranes – are integrated into the media. The result is an all-synthetic clarifying product l containing both a novel anion exchange functional nonwoven-supported hydrogel and a fine particle, bioburden reduction membrane.




